- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Paragangliomas.
Displaying page 1 of 1.
EudraCT Number: 2010-024621-20 | Sponsor Protocol Number: IGR2010/1715 | Start Date*: 2013-03-26 | |||||||||||
Sponsor Name:Institut Gustave Roussy | |||||||||||||
Full Title: First International Randomized Study in MAlignant Progressive Pheochromocytoma and Paraganglioma | |||||||||||||
Medical condition: Diagnosis of malignant PPGL, based on imaging or biopsy evidence of metastases in liver, bones, lungs and or lymph nodes, combined with at least one of two further confirmatory diagnoses: 1. diagno... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002951-39 | Sponsor Protocol Number: CAAA601A32201 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||||||||||||
Sponsor Name:Advanced Accelerator Applications SA | |||||||||||||||||||||||||||||||||
Full Title: A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheoc... | |||||||||||||||||||||||||||||||||
Medical condition: somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: SE (Prematurely Ended) FR (Trial now transitioned) PT (Prematurely Ended) PL (Trial now transitioned) BE (Completed) IT (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000194-93 | Sponsor Protocol Number: ENTRAP | Start Date*: 2021-12-22 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: Exendin PET/CT for imaging of paragangliomas | ||
Medical condition: Paraganglioma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002632-99 | Sponsor Protocol Number: ONC-NET-01 | Start Date*: 2011-10-14 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI | |||||||||||||
Full Title: SUTNET Trial: Biological and Clinical Phase II study of Sunitinib in patients with unresectable and/or metastatic pheochromocytoma/paraganglioma | |||||||||||||
Medical condition: Patients with unresectable and/or metastatic pheochromocytomas/paragangliomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005028-13 | Sponsor Protocol Number: MK-6482-015 | Start Date*: 2021-07-19 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendoc... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumor or von Hippel-Lindau (VHL) Disease-Associated Tumors or Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors with HIF... | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002867-41 | Sponsor Protocol Number: OPS-C-001/D-FR-01072-001 | Start Date*: 2015-12-10 | |||||||||||
Sponsor Name:Ipsen Pharma | |||||||||||||
Full Title: An international multi-center, open-label study to evaluate safety, tolerability, biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor positi... | |||||||||||||
Medical condition: Neuroendocrine tumors (NETs) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2023-000086-14 | Sponsor Protocol Number: IRST100.60 | Start Date*: 2023-04-14 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||
Full Title: Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial | |||||||||||||
Medical condition: Patients must have histologically or cytologically confirmation of neuroendocrine tumors or any other tumor histotype documented as sst-positive | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
